<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079091</url>
  </required_header>
  <id_info>
    <org_study_id>CS001</org_study_id>
    <nct_id>NCT01079091</nct_id>
  </id_info>
  <brief_title>Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units</brief_title>
  <acronym>HEPATICUS-1</acronym>
  <official_title>Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepa Wash GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepa Wash GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with compensated chronic liver disease who have an episode of acute deterioration of
      liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate.
      Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of
      recycled albumin dialysate. The new system has shown a high detoxification capacity in
      in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy
      of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care
      unit.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The foundations of our pilotstudy planning has changed.
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day mortality rate</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiorgan system failure</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (surrogate parameters)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on ventilation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days without extracorporeal treatment</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180d-mortality rate</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1y-mortality rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Acute on Chronic Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Medical Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepa Wash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the liver support system &quot;Hepa Wash&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hepa Wash</intervention_name>
    <description>Intervention frequency: 1-10 treatments (decision of the investigator)
Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)</description>
    <arm_group_label>Hepa Wash</arm_group_label>
    <other_name>Hepa Wash procedure</other_name>
    <other_name>the HIP1001 system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Medical Therapy</intervention_name>
    <description>Standard of care treatment</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with documented clinical or histological evidence of cirrhosis AND

          2. Acute decompensation in previously stable cirrhotic liver disease AND

          3. Bilirubin ≥ 2 mg/dl AND

          4. SOFA ≥ 9 calculated after 12 hours of optimal medical therapy AND

          5. Patient is in the intensive care unit AND

          6. Informed consent of the patient or the legal representative AND

          7. Patients are 18y or older AND

          8. Enrollment of patients within 96 hours of fulfilling inclusion criteria (1-5)

        Exclusion Criteria:

          1. Untreatable extrahepatic cholestasis

          2. Patient has a survival prognosis of less than 6 weeks because of a chronic disease
             (e.g. metastasizing cancer) and before the acute event which lead to the ICU
             admission.

          3. PaO2/FIO2 ≤ 100 mmHg (respiratory SOFA-score of 4)

          4. Patients who receive a vasopressor support of Dopamine &gt;15 µg/kg/min or epinephrine
             &gt;0.1 µg/kg/min or norepinephrine &gt;0.1 µg/kg/min (cardiovascular SOFA-score of 4)

          5. Patients with creatinine ≥5 mg/dl or urine output &lt;200 ml/day (renal SOFA-score of 4)

          6. Patients on kidney dialysis

          7. Patient with MELD-score of 40

          8. Mean arterial pressure ≤ 50 mmHg despite conventional medical treatment

          9. Patient testament excludes the use of life-prolonging measures

         10. Post-operative patients whose liver failure is related to liver surgery

         11. Uncontrolled seizures

         12. Active or uncontrolled bleeding

         13. Weight ≥ 120 kg

         14. Pregnancy

         15. Patient diagnosed with Creutzfeldt-Jakob disease

         16. Participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Huber, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>II Medizinische Klinik, Klinikum rechts der Isar, Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>II Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver failure</keyword>
  <keyword>Hepatic insufficiency</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Artificial liver</keyword>
  <keyword>Albumin dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

